Diabetic Dyslipidemia in Practice

Risk of CVD in Patients With Diabetic Dyslipidemia

People With Diabetes Have a Twofold to Threefold Increased Risk of Heart Disease

Incorporating Guidelines Into Clinical Practice

Treating Patients Who Have Diabetes With Statins

The Role of Nonstatin Therapy

Patients at High Risk Are Not Reaching Targets

A Review of PCSK9 Inhibitors

The Importance of the ODYSSEY DM-INSULIN Trial

ODYSSEY DM-INSULIN Trial

ODYSSEY DM-INSULIN Trial HbA1c and Glucose Levels

The Importance of the ODYSSEY DM-DYSLIPIDEMIA Trial

ODYSSEY DM-DYSLIPIDEMIA Trial

CVOT Data on PCSK9 Inhibitor Evolocumab in Patients: FOURIER Trial

Upcoming CVOT Data on PCSK9 Inhibitors in Patients: ODYSSEY OUTCOMES

Implications for Clinical Practice How to Treat Patients at Risk?

Educating Patients on Use of PCSK9 Inhibitors

Role of Multispecialty Care for Effective Treatment

Concluding Remarks

Abbreviations

Abbreviations (cont)